Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 15Esophageal Neoplasms 10Colorectal Neoplasms 10Rectal Neoplasms 7Adenocarcinoma Of Esophagus 7Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Gastroesophageal Reflux 4Polyps 3Pathologic Complete Response 3Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Carcinoma 3Precancerous Conditions 2Hyperplasia 2Fistula 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenomatous Polyposis Coli 2Adenocarcinoma 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Signs and Symptoms 1Sarcoma 1

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Endoscopy × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡